Wilms' tumor gene 1 (WT1) is overexpressed in the majority (70-90%) of acute leukemias and has been identified as an independent adverse prognostic factor, a convenient minimal residual disease (MRD) marker and potential therapeutic target in acute leukemia. We examined WT1 expression patterns in childhood acute lymphoblastic leukemia (ALL), where its clinical implication remains unclear. Using a real-time quantitative PCR designed according to Europe Against Cancer Program recommendations, we evaluated WT1 expression in 125 consecutively enrolled patients with childhood ALL (106 BCP-ALL, 19 T-ALL) and compared it with physiologic WT1 expression in normal and regenerating bone marrow (BM). In childhood B-cell precursor (BCP)-ALL, we detected a wide range of WT1 levels (5 logs) with a median WT1 expression close to that of normal BM. WT1 expression in childhood T-ALL was significantly higher than in BCP-ALL (Po0.001). Patients with MLL-AF4 translocation showed high WT1 overexpression (Po0.01) compared to patients with other or no chromosomal aberrations. Older children (X10 years) expressed higher WT1 levels than children under 10 years of age (Po0.001), while there was no difference in WT1 expression in patients with peripheral blood leukocyte count (WBC) X50 Â 10 9 /l and lower. Analysis of relapsed cases (14/125) indicated that an abnormal increase or decrease in WT1 expression was associated with a significantly increased risk of relapse (P ¼ 0.0006), and this prognostic impact of WT1 was independent of other main risk factors (P ¼ 0.0012). In summary, our study suggests that WT1 expression in childhood ALL is very variable and much lower than in AML or adult ALL. WT1, thus, will not be a useful marker for MRD detection in childhood ALL, however, it does represent a potential independent risk factor in childhood ALL. Interestingly, a proportion of childhood ALL patients express WT1 at levels below the normal physiological BM WT1 expression, and this reduced WT1 expression appears to be associated with a higher risk of relapse.
Introduction
Wilms' tumor gene 1 (WT1) has been evaluated as a novel potential prognostic factor, minimal residual disease (MRD) marker and therapeutic target in acute leukemia.
WT1 is located on chromosome 11p13 and encodes a zincfinger transcription factor. Post-transcriptional mRNA modifications and the presence of possible several transcription initiation sites give rise to a number of different WT1 protein isoforms (at least 32) that are localized in specific subcellular and subnuclear regions and show different, partially overlapping but distinct functions. [1] [2] [3] [4] [5] [6] [7] [8] [9] WT1 regulates the transcription of a variety of target genes and is involved in post-transcriptional mRNA processing. It can act as a transcriptional activator or repressor, depending on the WT1 isoform, interactions with other isoforms and with other transcription regulators. In this way, WT1 can control proliferation, differentiation, cell cycle and apoptosis; however, its regulatory properties have not yet been fully understood. [1] [2] [3] 5, 6, [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] WT1 is necessary for normal development of mesothelial tissues including the hematopoietic system. Hematopoietic precursors show transient biphasic WT1 overexpression, which has a stage-specific effect: WT1 maintains primitive stem cells in a quiescent state, while it promotes differentiation of more mature lineage-committed progenitors. [20] [21] [22] Alterations of WT1 expression (both under-or overexpression) have been described in a number of malignancies and premalignant syndromes. Remarkably, WT1 overexpression has been found in 80-90% of acute myeloid leukemia (AML) and 70-90% of acute lymphoblastic leukemia (ALL) patients, with an even higher frequency at relapse. 2, 4, 5, The upregulation of WT1 is present in all leukemia subtypes. In AML, several authors detected lower levels of WT1 expression in more differentiated AML subtypes (M5) than in less differentiated subtypes, 29, 32 while others could not support this finding. 43 In ALL, a higher frequency of WT1 expression was found in B-ALL by one author 26 and in T-ALL by another. 27 In several studies, high levels of WT1 expression at diagnosis have been identified as an independent prognostic factor associated with unfavorable prognosis in acute leukemia, particularly in AML, 32, 39, 42 but other studies have failed to confirm this observation. 34, 35 An increasing number of studies have indicated the prognostic and predictive value of WT1 as a marker for minimal residual disease (MRD) monitoring during patient follow-up. 29, 30, 32, 39, 41, 43 WT1 was demonstrated to be a strong predictor of the outcome of allogeneic stem cell transplantation for acute leukemia, 44 but not for BCR-ABL-positive ALL. 45 WT1
overexpression was also detected in the cerebrospinal fluid of patients with B-ALL where it showed a strong association with disease relapse. 46 The majority of acute leukemias express the normal, wild-type WT1 gene. In addition, point mutations and small deletions or insertions may also occur and have been identified in approximately 10-20% of acute leukemias, predominantly in biphenotypic and AML, but rarely in ALL. In AML, these alterations were shown to be associated with an unfavorable prognosis. 1, 2, 5 A possible imbalance in the ratio of the main WT1 isoforms in acute leukemia and its effect will require further investigation. 47, 48 The WT1 protein possesses immunogenic properties and has been successfully tested as a target for antileukemic vaccines. 2, 5, [49] [50] [51] [52] [53] The discrepancies between different authors and studies on the expression and role of WT1 in acute leukemia may result from the nonstandardized techniques of WT1 detection and quantification employed (qualitative PCR vs real-time quantitative PCR (RQ-PCR), relative vs absolute methods of the gene expression quantification, different control genes, type and number of negative/normal controls), the type of samples evaluated (bone marrow (BM) vs peripheral blood (PB)), as well as the size and character of the patient groups examined.
In this study, we focused on evaluation of WT1 expression and its clinical implications in childhood ALL, where WT1 has been least studied and its impact remains most controversial.
Materials and methods

Samples
Patients samples. After ethical committee approval and informed consent, diagnostic BM samples from 125 patients with childhood ALL (60 from Our Lady's Hospital for Sick Children in Crumlin, Dublin, Ireland, and 65 from University Hospital in Prague -Motol, Czech Republic) were collected on a consecutive basis from January 2001 to May 2004 and analyzed. The male/female ratio of the patients was 1.3:1; the median age was 5 years (range 0-16 years). They involved 106 B-cell precursor (BCP) ALL (including 1 hybrid ALL) and 19 T-ALL cases. Among them, 27 patients had chromosomal translocations confirmed by cytogenetics and/or PCR: 22 TEL-AML1 (ETV6-RUNX1), three MLL-AF4 and two BCR-ABL (no patient from the Irish group expressed E2A-PBX1 translocation; Czech patients were not screened for this aberration). The main risk factors defined as age p1 or X10 years and WBCX50 Â 10 9 /l at diagnosis were present in 3, 35 and 30 patients, respectively. Patients were treated according to standard protocols, UKALL97/99 study in Ireland, ALL-BFM 95, POG9407 and Interfant in the Czech republic. The median follow-up is 32 months (range 1-47); during this period 13 of the 120 patients relapsed, one showed no response with continual disease progression since diagnosis and 11 patients died (Table 1) .
Because of the small number of patients with MLL-AF4 and BCR-ABL translocations enrolled sequentially, further patients with these translocations (one MLL-AF4 and nine BCR-ABL, all BCP-ALL) were selected retrospectively from patients diagnosed in previous years with stored BM RNA available. These cases were included only in analysis of WT1 expression in different chromosomal translocations.
Donors samples.
To evaluate WT1 expression in normal hematopoietic tissues, PB (n ¼ 6), BM (n ¼ 9) and peripheral stem cell concentrate (PSC, n ¼ 1) obtained after informed consent from normal healthy adult donors were examined.
In addition, MRD-negative regenerating BM taken from patients with childhood ALL during the course of therapy was studied. This included 30 follow-up samples (day 29, weeks 7, 12, 16, months 6 and 12) from seven patients with TEL-AML1 translocation enrolled in this study.
Methods
Sample processing. BM, PB or PSC were collected into sterile tubes with anticoagulant (ACD, K 2 or K 3 EDTA) and immediately transported to the lab at room temperature. The initial processing of the samples was performed within 12 h after their collection, in most cases within the first 4 h. Mononuclear cells were separated from the samples by centrifugation on density gradient medium (Lymphoprep). RNA was isolated from the samples using an RNeasy Mini Kit (Qiagen), and the concentration of extracted RNA was evaluated by spectrophotometry (SPEC). The cDNA synthesis was performed according to the Europe Against Cancer Program (EAC) recommendations 54, 55 starting from 1 mg of total RNA or as described previously. 32 RQ-PCR for WT1. RQ-PCR for the detection and the quantification of WT1 was developed according to EAC protocols. 54 Primers and a probe were designed using PrimerExpress 2.0 software with the forward primer located on exon 6, the reverse primer on exon 7 and the 6FAM-and TAMRAlabeled probe located on the exon 6/7 boundary. The reaction conditions suggested by EAC were used ( Table 2) . As a control gene (CG), ABL was detected in all samples without BCR-ABL translocation, where b-2-microglobulin (B2M) was used instead. The RQ-PCR reaction was performed on the ABI PRISM 7700 Sequence Detection System (Applied Biosystems) or iQCycler (Biorad). Detection of WT1 was carried out in a triplicate reaction, and detection of CG and calibrators for both WT1 and CG in duplicate. For WT1 and CG the threshold was set at 0.1 to be in the exponential phase, and the baseline between 3 and 15, except for B2M with the baseline 3-10. A sample was considered positive if at least one of the triplicate or duplicate . Escherichia coli rRNA was used as a negative control. The specificity, sensitivity and efficiency of the assay were validated on calibrators, K-562 cell line (DSMZ, ACC 10), donor and patient samples. With WT1 plasmid calibrators, the standard curve generated a slope of -3.45 and an intercept of 39.4 C t . The mean C t value obtained for 10 6 WT1 copies was 18.870.1. The lowest copy number used was 10 1 WT1 copies, which gave positive and reproducible results in all experiments (and all reactions carried in duplicate or triplicate), with the mean C t being 36.170.8. With the K-562 cell line RNA dilution series, the standard curve generated a slope of -3.34 and an intercept of 21.7; the reproducible sensitivity reached -5 log with the mean C t being 38.271.4 (Table 2 ). Validation analysis (Bulletin 2, 10/2001, Applied Biosystems) confirmed approximately equal efficiency of WT1 and CG (ABL, B2M) RQ-PCR reactions, with the absolute values of the slopes of WT1/ABL plasmid calibrator standard curve and WT1/B2M K-562 RNA dilution standard curve o0.1 (0.055 and 0.075, respectively) and thus applicability of the comparative DDC t method.
WT1 plasmid DNA calibrators. The WT1 sequence obtained from the first round PCR was cloned into a PCR 2.1-TOPO vector and this was transformed into a TOP10 E. coli strain, using the TOPO TA Cloning Kit (Invitrogen). The selected clones were screened for the presence of the insert by PCR and then sequenced for confirmation. After bulk production, the plasmids were extracted using the HiSpeed Plasmid Midi Kit (Qiagen), quantified by SPEC and linearized with EcoRI (Invitrogen) restriction. The digested plasmid was serially diluted in a solution of Tris/EDTA/E. coli 16S and 23S rRNA (Roche), and a set of WT1 calibrators with final concentrations of 10 6 , 10 Detection of MRD by detection of TEL-AML1 translocation. TEL-AML1 translocation was detected, quantified and used for MRD monitoring according to BIOMED-1 and EAC recommendations.
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Analysis of the results and statistical considerations.
Results were analyzed using Microsoft Excel, Prism 4 and Instat 3 (both GraphPad) and SPSS 10 software. Group comparisons were performed by the Mann-Whitney nonparametric U test and the Kruskal-Wallis nonparametric test with Dunn's multiple comparisons post-test. Survival analyses were calculated by Kaplan-Meier survival curves and the log rank test. Univariate and multivariate analyses were performed using Cox proportional hazards model with data categorized into three groups or with data transformed (log 2 transformation of WT1 expression values and the absolute value of their subtraction from the mean). (Figure 1 ). MRD-negative regenerating BM taken at different time-points during the course of antileukemic therapy exhibited median WT1 expression almost identical to that of normal BM (median 28; range 1-100 Â 10 À4 WT1/ABL NCN). The range of detected WT1 levels was wider in comparison with normal BM due to lower and more variable WT1 expression in early follow-up samples (day 29 -week 16). In later follow-up samples (months 6 and 12), WT1 expression was quite comparable to normal BM (Table 3 and Figure 1 ).
The quantification of WT1 expression in normal samples using the other control gene, B2M (WT1/100 B2M NCN), gave a good correlation of results for the BM (median 25; range 18-52 Â 10 À4 WT1/100 B2M NCN). In PB, WT1 levels calculated to B2M were lower (0.7; 0.1-1) than when calculated to ABL, and so was the WT1 expression in PSC (1 Â 10 À4 ). Based on the control samples examined and allowing for eventual further variations in physiologic WT1 expression, normal ranges of WT1 expression in BM were defined as 75% of the minimal and 125% of the maximal WT1 expression observed in normal BM (15-150 Â 10 À4 WT1/ABL NCN).
WT1 expression in childhood ALL
In childhood BCP-ALL, WT1 expression in diagnostic BM samples varied within a wide range, over 5 logs (median 24.5; range 0-11 197 Â 10 À4 WT1/CG NCN) ( Table 3 and Figure 2 ). However, the majority of patients had WT1 levels close to those of normal BM (see also Figure 4 ), and there was no significant difference between median WT1 expression in BCP-ALL and normal BM (P40.05). Apart from several patients with considerable WT1 overexpression, there was also a group of patients (almost one third) with very low WT1 expression even below the minimal WT1 levels in normal BM, including two patients in whom WT1 was undetectable.
In contrast to BCP-ALL, WT1 overexpression was found in most of the childhood T-ALL cases (median 485; range 23-6295 Â 10 À4 WT1/CG NCN) ( Table 3 and Figure 2 ). Although the difference in the median WT1 expression between childhood T-ALL and normal BM did not reach statistical significance (P40.05), WT1 expression in childhood T-ALL was significantly higher than in B-ALL (Po0.001). Wilms
Among all examined childhood ALL samples, even those with WT1 overexpression, none expressed WT1 in levels at least 2 log above the WT1 expression detected in normal BM.
WT1 expression in childhood ALL with different chromosomal aberrations
WT1 expression was analyzed in subgroups of childhood BCP-ALL (including the hybrid ALL) with the following chromosomal aberrations: TEL-AML1 (ETV6-RUNX1) translocation (the most frequent and prognostically rather favorable), MLL-AF4 and BCR-ABL translocations (both prognostically unfavorable) and no/ other aberrations (Table 3 and Figure 2 ). Patients with MLL-AF4 translocation expressed remarkably high WT1 levels (median 7302; range 4331-11 197 Â 10 À4 WT1/CG NCN) in comparison with all the other subgroups (Po0.01), while there was no significant difference in WT1 expression between patients with TEL-AML1, BCR-ABL and no/other aberrations (P40.05).
WT1 expression in childhood ALL and main risk factors -age, WBC
The relation between age and leukocyte count at diagnosis (the two principal risk factors in childhood ALL) and WT1 expression was studied. Children at the age X10 years had significantly higher WT1 expression (median 380; range 1-11 197 Â 10 À4 WT1/CG NCN) than children between 1 and 10 years of age (21; 0-6295) (Po0.001). Also, infants p1 year showed high WT1 expression (9006; 5597-9322) with the difference being statistically significant (Po0.01), but this finding is influenced by the fact that two of the three patients also had MLL-AF4 translocation (Table 3 and Figure 3 ).
In patients with PB WBC o50 Â 10 9 /l and leukocytosis X50 Â 10 9 /l, no major difference in WT1 expression was observed (P40.05) ( Table 3 and Figure 3 ).
WT1 expression in childhood ALL and the risk of relapse
The 14 patients who have relapsed (including 1 with no response) did not differ in the median or range of WT1 expression (median 13; range 0-11 197 Â 10 À4 WT1/CG NCN) from the rest of the patients remaining in remission (P40.05) ( Table 3 and Figure 4) . However, if all childhood ALL patients were divided into three groups with abnormally low (o15), normal (15-150) or abnormally high (4150) WT1 expression (see the definition of normal BM WT1 expression given previously), a significant difference was observed in relapsefree survival between these groups (P ¼ 0.012; for low vs normal WT1 P ¼ 0.024, for high vs normal WT1 P ¼ 0.015) ( Table 3 and Figure 4 ). Patients with both low and high WT1 expression had an increased risk of relapse with hazard ratios of 11.6 (95% CI 1.4-97) and 13.5 (1.7-111), respectively. In multivariate Wilms' tumor gene 1 (WT1) expression L Boublikova et al analysis including age and WBC (the presence of unfavorable chromosomal aberrations BCR-ABL and MLL-AF4 was not included because of very few cases in the cohort of patients; both two BCR-ABL positive patients and none of the three patients with MLL-AF4 relapsed), WT1 under-and overexpression proved to be an independent risk factor of relapse (P ¼ 0.014 and 0.049, respectively). It was more pronounced for patients with abnormally low WT1 expression, while in patients with abnormally high WT1 levels the relapse was often associated with the age over 10 years. However, this may reflect the fact that in the whole group of patients over 10 years of age, higher WT1 levels were detected. Similar, even clearer results were obtained when univariate and multivariate analyses were performed with the individual values of WT1 expression (their absolute difference from the mean WT1 expression in ALL). In univariate analysis, increase or decrease in WT1 levels from the mean WT1 expression was associated with significantly increased risk of relapse (P ¼ 0.0006) with the hazard ratio 1.5 (1.2-1.9)/two-fold increase or decrease of WT1; the independence of the WT1 prognostic value was confirmed by multivariate analysis (P ¼ 0.0012).
Discussion
Although promising, the significance of WT1 as a prognostic factor, MRD marker and a possible target for immunotherapy in acute leukemia still remains unclear, and the role of WT1 in the process of leukemogenesis is not well understood. To elucidate the WT1 expression patterns and its clinical implications in childhood ALL, we established a reliable assay for WT1 detection and quantification, and using this studied WT1 in a representative group of normal controls and childhood ALL patients.
In the vast majority of leukemia cases, the abnormality in WT1 expression is only of a quantitative character. Therefore, an exact method that enables sensitive detection with precise, preferably absolute quantification of WT1 is a necessary prerequisite for WT1 analysis in acute leukemia. It is probable that the inconsistent methodology contributed most of all to the discrepant results of some studies. We designed and set up the RQ-PCR of WT1 according to the EAC recommendations (a proposed standard for detection of fusion genes and MRD in leukemia and suggested approach for detection of gene overexpression), 54 and ensured that all parameters of the reaction comply with the EAC required criteria. This RQ-PCR could thus be considered as an adequate assay for investigation of WT1 expression in childhood ALL.
To evaluate the normal background WT1 expression, we analyzed WT1 in control samples -PB, BM and PSC from healthy adult donors and MRD-negative regenerating BM from childhood ALL patients. WT1 is physiologically expressed in normal hematopoietic cells. The WT1 expression has been well studied in CD34 þ hematopoietic precursors, where WT1 may reach levels similar to those found in leukemic cells. 
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Contrary to leukemic cells, WT1 in normal hematopoietic precursors exhibits a typical expression pattern (transitional biphasic) with well-defined functions. [20] [21] [22] Except for very early investigations, 4 WT1 expression has been identified in normal BM and PSC controls or CD34 þ concentrates in all further studies, either in a proportion 25, 37, 39, 42 or all 30, 43, 44 of the samples tested. In agreement with the latter studies, we could detect WT1 expression in all analyzed normal BM and PSC samples. The absolute values correspond well with the results reported by Cilloni et al., 30 who employed a similar RQ-PCR technique for WT1 detection, and are higher than those referred by several other authors who also used the WT1/CG NCN approach for WT1 quantification. 39, 42, 43 WT1 expression in normal PB has not been specifically studied and the function of WT1 in PB cells is not known. While some authors did not find any WT1 expression in normal PB, 4, 29, 32, 41, 42 others detected the presence of WT1 in a proportion of samples. 30, 37, 43, 45 We found low levels of WT1 in all PB samples analyzed, again in an amount very similar to Cilloni's findings 30 and higher than those observed by other authors, 43, 45 which may reflect a higher sensitivity of our method.
WT1 expression in regenerating BM has been studied mostly indirectly, by evaluation of WT1 levels in follow-up samples for the purpose of MRD monitoring. 32, 39, 43 From these studies, it seemed that there is no major difference in WT1 expression in normal BM and BM during various stages of antileukemic treatment. In addition, Cilloni et al. 30 found very similar WT1 expression in the normal and regenerating BM samples examined. Our results can confirm that although WT1 expression in MRD-negative BM taken during the induction therapy of childhood ALL tends to reach lower levels, WT1 expression in BM during the later phases of antileukemic therapy is practically identical to normal BM and thus no significant difference in WT1 expression between the normal and regenerating BM can be observed.
With respect to the normal ranges of WT1 expression, we analyzed WT1 in a representative group of childhood ALL patients. In childhood BCP-ALL, we detected a very wide range of WT1 expression levels but despite this, majority of the patients had WT1 expression similar to normal BM and there was no significant difference in the median WT1 expression between normal BM and childhood BCP-ALL. The highest detected WT1 values were up to 2 log above the normal BM WT1 expression and, on the other hand, a proportion of patients showed WT1 expression below the normal BM WT1 levels. Contrary to BCP-ALL, most of the childhood T-ALL patients showed WT1overexpression, with the median being significantly higher than in BCP-ALL patients. The highest WT1 values in T-ALL were similar to the upper range of WT1 expression in BCP-ALL, but no patient expressed WT1 lower than normal BM levels. Although it is agreed that WT1 overexpression, in terms of frequency and WT1 levels, is lower in ALL than AML and probably lower in children than adults, 4, [25] [26] [27] 29, 30, 32, 35, 37, 39 such a pattern of WT1 expression in acute leukemia has not been described before. In previous studies, WT1 overexpression above the normal values was found in the majority or all of the ALL samples, 4, [25] [26] [27] 29, 30, 35, 37, 39, 41 and WT1 expression in acute leukemia below the ranges of normal controls was never detected. Most of the studies did not distinguish between B and T-ALL; in those analyzing these subtypes separately, controversial results were found, with higher WT1 overexpression detected in B-ALL in some of them 26 and in T-ALL in others. 27 However, these studies investigated WT1 mostly in adult ALL patients or in heterogenous groups of children and adults, 4, 25, 29, 30, 39 in PB samples, 29 ,41 using potentially lesssensitive PCR techniques of WT1 detection 4, [25] [26] [27] 35, 37, 39 and with a limited number or type of normal controls tested. 4, [25] [26] [27] 35 The highly variable WT1 levels, including the WT1 underexpression, that we observed in childhood ALL patients at diagnosis are related only to the leukemic disease and could not be even partially attributed to individual constitutional variations in WT1 expression in different patients. This is suggested by the finding that the MRD-negative follow-up samples exhibited very uniform WT1 expression, reflecting normal BM ranges, although these patients showed quite variable WT1 levels in their diagnostic leukemic samples.
In the cytogenetically defined subgroups, our patients with MLL-AF4 translocation had extremely high WT1 levels compared to all the other patients. Patients with BCR-ABL p190 translocation also tended to have higher WT1 expression but it did not reach statistical significance. These findings are in agreement with the results of other authors who described high WT1 overexpression in ALL with these two translocations. 30 We further investigated WT1 expression in relation to the two main risk factors -age and leukocyte count. While there was no significant difference in WT1 levels between patients with peripheral WBC below and over 50 Â 10 9 /l, patients between 1 and 10 years of age had lower WT1 expression than older patients. Apart from the possible association of WT1 overexpression with one of the prognostically adverse factors, this finding may also suggest that WT1 expression in ALL increases with age and may explain why the overall WT1 detected in our childhood patients is lower than the values reported for adult ALL patients. Infants below 1 year also showed high WT1 expression but as the majority of them expressed MLL-AF4 translocation, the effect of the very young age on WT1 expression could not be assessed.
Recent studies have identified WT1 overexpression as an independent adverse prognostic factor in acute leukemia associated with an increased risk of relapse. 32, 39, 42 Among our childhood ALL patients there was a trend toward higher WT1 expression in those who relapsed but this did not reach statistical significance. But interestingly, Kaplan-Meier curves showed that, after dividing patients into three groups with low, normal and high WT1 levels, patients with WT1 overexpression, together with patients with WT1 underexpression, had a significantly higher risk of relapse (12 and 14 times, respectively) than patients with WT1 within the physiologic range. This result was supported by univariate analysis of individual WT1 expression values showing a significantly increased risk of relapse (1.5/2 Â ) with WT1 increasing or decreasing from the mean WT1 expression in childhood ALL. By multivariate analysis, in both cases, WT1 proved to be an independent risk factor. These findings may thus confirm the prognostic impact of WT1 overexpression in childhood ALL and, at the same time, bring attention to the clinical significance of the abnormally low detected WT1 levels in some of the childhood ALL patients. Although it is not possible to arrive at definitive conclusion because of the limited number of relapsed patients with WT1 underexpression analyzed, the phenomenon of WT1 underexpression should be recognized and its presence and effect in acute leukemia could be better elucidated by further studies. From the functional point of view, the consequences of WT1 underexpression may only be hypothesized, as the role of WT1 in the process of leukemia development has not yet been sufficiently clarified. 1, 3, 5, 10 It becomes more and more apparent that the regulatory effects of WT1 on cellular proliferation, differentiation and apoptosis are quite complex, depending on the cooperation and the interactions among different WT1 isoforms, a number of other factors and regulators and the actual status of the cell. In case WT1 is directly involved in the leukemogenic pathways, it seems possible that any deviation from normal WT1 expression and function may lead to disruption of the regulatory networks, facilitating leukemic transformation and/or growth. On the other hand, if changes in WT1 expression are rather a consequence than a cause of the leukemic process, WT1 overexpression may reflect the degree of malignant transformation or proliferation. WT1 underexpression could then represent a loss of normal WT1 expression during the progress of the disease or may be a result of leukemia originating from hematopoietic precursors at the stage of their development when they normally express very low WT1 levels. Whichever is the case, empirically we know that mutations negatively affecting WT1 function have been described in acute leukemia and found to be associated with unfavorable prognosis, 1,2,5 and WT1 underexpression and mutations altering WT1 functions are known in Wilms' tumor and other solid malignancies. 1, 3, 5, 6, 10 WT1 overexpression has been successfully used as a marker for detection of minimal residual disease in acute leukemia, particularly in AML. 29, 30, 32, 39, 41, 43 We investigated the potential of WT1 for MRD monitoring in childhood ALL. The principal requirement of a method suitable for MRD detection is its high specificity with a sensitivity of at least 10 À3 ideally 10 À4 and more. 57, 58 The WT1 expression that we detected in childhood ALL patients was very variable and none of the 125 patients had WT1 at least 2 logs or higher above the background WT1 expression in the normal BM. It is therefore possible to conclude that WT1 is not a useful marker for MRD monitoring in childhood ALL.
Conclusion
The current management of childhood ALL relies on patient stratification and risk-directed therapy based on prognostic factors and initial response evaluation, recently including minimal residual disease monitoring. Although the system of risk assessment as well as the techniques of MRD detection are well established and the treatment outcome is excellent, with 70-80% of patients achieving long-term remission, molecular aberrations that could act as new prognostic factors, MRD markers and therapeutic targets are investigated with the aim to improve further the prognosis of patients with childhood ALL. Among these, WT1 is one of the most promising. The role of WT1 in leukemogenesis is yet to be defined but in an increasing number of studies, WT1 overexpression has been identified as a potential independent adverse prognostic factor in acute leukemia, a suitable marker for MRD monitoring, mainly in AML, and a promising target for immunotherapy in leukemia and other malignancies. Our study showed that WT1 expression in childhood ALL is very variable and, in general, much lower than in AML or adult ALL. Thus, WT1 will not be a useful marker for MRD detection in childhood ALL. But like in other types of acute leukemia, also, childhood ALL patients with WT1 overexpression have an increased risk of relapse, and WT1 overexpression represents a potential additional independent risk factor in childhood ALL. Interestingly, a proportion of childhood ALL patients express WT1 in levels below the normal physiological BM WT1 expression, and this WT1 underexpression also seems to be associated with an increased risk of relapse. These results only support the complex model of WT1 regulatory effects in normal and malignant hematopoiesis. Further studies, both functional and clinical, will be necessary to clarify the WT1 expression patterns and functions in acute leukemia.
